MilliporeSigma acquires AmpTec to expand mRNA capabilities
by CM Staff
Adds to MilliporeSigma's lipid manufacturing expertise, providing an integrated offering across mRNA value chain
MilliporeSigma’s acquisition of AmpTec and its PCR-technology builds on its extensive expertise in lipids manufacturing, allowing MilliporeSigma to provide a truly unique and integrated offering across the mRNA value chain, which will significantly decrease supply chain complexity and enhance speed-to-market.
BURLINGTON — On Jan. 7, MilliporeSigma announced the acquisition of AmpTec, a Hamburg, Germany-based, mRNA contract development and manufacturing organization (CDMO). The deal strengthens MilliporeSigma’s capabilities to develop and manufacture mRNA for its customers for use in vaccines, treatments and diagnostics applicable in Covid-19 and many other diseases. Financial terms were not disclosed.
“The success of mRNA-based vaccines for Covid-19 lays the path to accelerate the development of these therapeutics for many other diseases,” said Stefan Oschmann, Chairman of the Executive Board and CEO, Merck KGaA Darmstadt, Germany. “By combining AmpTec’s PCR-based mRNA technology with our extensive expertise in lipids manufacturing, we are able to provide a truly differentiated and integrated offering across the mRNA value chain, which will significantly decrease supply chain complexity and enhance speed-to-market. This transaction is another important step to support the constant growth of our Life Science business through tailored, small-scale acquisitions with high impact.”
MilliporeSigma is investing in mRNA as a modality and will scale up this technology both at AmpTec’s existing site in Hamburg and at MilliporeSigma’s global headquarters in Darmstadt, Germany.
